首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

市場調查報告書

商品編碼

1738602

2026 年至 2032 年 G-CSF 生物相似藥銷售市場（按類型、應用、分銷管道和地區）

G-CSF Biosimilars Sales Market Size By Type (Short-acting, Long-acting), Application (Oncology, Blood Disorders, Chronic Diseases), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) And Region For 2026-2032

出版日期: 2025年05月12日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

G-CSF生物相似藥銷售市場－2026年至2032年

由於參考生技藥品專利到期、癌症發病率上升以及對經濟有效治療方案的需求不斷成長，G-CSF 生物相似藥市場正經歷強勁成長。有利的法規結構、不斷完善的醫療基礎設施以及國內和已開發市場對生物相似藥的日益普及，進一步推動了這一發展。預計這將推動市場規模在 2024 年突破 118.6 億美元，到 2032 年達到 220.3 億美元。

除了這些成長要素外，市場還見證了研發投入的增加，以改善製造流程和產品開發。人們越來越關注改善患者獲得可負擔生物療法的管道，以及醫療保健提供者對生物相似藥的接受度不斷提高，這為市場擴張鋪平了新的途徑。此外，全球醫療保健系統日益重視基於以金額為準的醫療保健和成本控制策略，也推動了各地區市場的成長。生物相似藥需求的不斷成長將推動市場在2026年至2032年間以8.88%的複合年成長率成長。

全球 G-CSF 生物相似藥銷售市場定義/概述

G-CSF生物相似藥是與用於刺激化療或嚴重嗜中性白血球低下症患者白血球生成的參考顆粒細胞增生因子高度相似的化療製品。這些生物相似生技藥品已通過全面的比較測試，證明其品質、安全性和有效性與參考產品相當。

G-CSF生物相似藥的開發和生產需要先進的生物技術製程和嚴格的品管。每種產品都經過廣泛的特性鑑定和臨床測試，以確保與參考產品具有治療等效性，同時為醫療保健系統和患者提供成本優勢。

G-CSF生物相似藥市場前景光明，新技術和新應用具有成長潛力。隨著生產流程的進步、跨地區監管協調的加強以及新型給藥系統的開發，預計將出現新的發展。適應症的潛在擴展以及對個人化醫療的日益關注，有望帶來更加多樣化和高效的市場供應。

日益加重的癌症負擔將如何推動 G-CSF 生物相似藥銷售市場的成長？

全球癌症發生率的上升正顯著推動G-CSF生物相似藥市場的成長。隨著全球癌症發生率持續上升，對支持性護理治療的需求激增，包括用於治療化療嗜中性白血球低下症的G-CSF製劑。這一領域對於改善患者預後和促進最佳化療給藥方案至關重要。具有成本效益的生物相似藥製劑的出現，使更多患者，尤其是在醫療資源有限的地區，更容易獲得這些重要的治療方法。此外，生物相似藥開發和製造流程的進步在保持成本優勢的同時提高了產品質量，從而增強了市場吸引力。醫療保健專業人員對生物相似藥有效性和安全性的認知不斷提高，也推動了市場的擴張。因此，由於癌症患者數量的增加、對有效支持性護理的需求以及醫療保健界生物類似藥技術和教育的持續改進等多種因素的共同作用，G-CSF生物相似藥市場正在經歷強勁成長。

複雜製造流程的挑戰如何影響 G-CSF 生物相似藥市場的成長？

生產流程的複雜性是G-CSF生物相似藥市場成長面臨的重大挑戰。生產生質類似藥需要先進的設備、先進的技術、熟練的人力和大量的投資。此外，保持不同生產批次的產品品質一致性並滿足監管標準對製造商而言是一項持續的挑戰。對於進入市場的中小型企業來說，這種情況尤其具有挑戰性，因為它們經常會遇到資源限制和技術障礙，從而限制其產能。此外，對產品品質和監管合規性的日益關注也增加了生產的複雜性和成本。為了應對這些挑戰，該行業正在投資先進的生產技術和製程最佳化，以提高效率並降低生產成本，同時維持產品品質。這些努力旨在創造一個更永續的生產環境，使現有和新參與企業都能在競爭激烈的G-CSF生物相似藥市場中蓬勃發展，同時確保有需要的患者能夠獲得高品質的治療。

The G-CSF Biosimilars Sales Market is experiencing robust growth driven by patent expirations of reference biologics, increasing cancer incidence rates, and growing demand for cost-effective treatment options. The market expansion is further supported by favorable regulatory frameworks, improving healthcare infrastructure, and rising adoption of biosimilars in both developed and emerging markets. This is likely to enable the market size to surpass USD 11.86 Billion valued in 2024 to reach a valuation of around USD 22.03 Billion by 2032.

In addition to these growth factors, the market is witnessing increased investment in research and development for enhanced manufacturing processes and product development. The focus on improving patient access to affordable biological treatments and the rising acceptance of biosimilars among healthcare providers is opening new avenues for market expansion. Moreover, the growing emphasis on value-based healthcare and cost containment strategies by healthcare systems worldwide is driving regional market growth. The rising demand for biosimilars is enabling the market to grow at a CAGR of 8.88% from 2026 to 2032.

Global G-CSF Biosimilars Sales Market: Definition/Overview

G-CSF biosimilars are biologic medical products that are highly similar to reference granulocyte colony-stimulating factors used to stimulate the production of white blood cells in patients undergoing chemotherapy or those with severe neutropenia. These biosimilars have demonstrated comparable quality, safety, and efficacy to their reference products through comprehensive comparative studies.

The development and manufacturing of G-CSF biosimilars involve sophisticated biotechnology processes and stringent quality controls. Each product undergoes extensive characterization and clinical testing to ensure therapeutic equivalence to the reference product while offering cost advantages to healthcare systems and patients.

The future scope of the G-CSF biosimilars market is promising, with potential for growth in emerging technologies and applications. Advancements in manufacturing processes, increasing regulatory harmonization across regions, and the development of novel drug delivery systems are expected to open new market opportunities. The potential for expanding indications and the growing focus on personalized medicine may lead to more diverse and effective market offerings.

How does the Increasing Cancer Burden Drive the Growth of The G-CSF Biosimilars Market?

The rising global cancer burden significantly drives growth in the G-CSF Biosimilars Market. As cancer incidence rates continue to escalate worldwide, the demand for supportive care treatments, including G-CSF products for managing chemotherapy-induced neutropenia, has surged. This segment is crucial for improving patient outcomes and facilitating optimal chemotherapy dosing schedules. The availability of cost-effective biosimilar alternatives has made these essential treatments more accessible to a broader patient population, especially in regions with limited healthcare resources. Furthermore, advancements in biosimilar development and manufacturing processes have improved product quality while retaining cost advantages, contributing to their attractiveness in the market. The increasing awareness among healthcare providers regarding the efficacy and safety of biosimilars is also fostering market expansion. As a result, the G-CSF biosimilars market is witnessing robust growth, driven by a combination of factors such as rising cancer cases, the need for effective supportive care, and continuous improvements in biosimilar technology and education within the healthcare community.

How is the Challenge of Complex Manufacturing Processes Impacting the Growth of The G-CSF Biosimilars Market?

The complexity of manufacturing processes poses a significant challenge impacting the growth of the G-CSF Biosimilars Market. Producing biosimilars necessitates sophisticated facilities, advanced technology, and highly skilled personnel, leading to substantial investment requirements. Additionally, maintaining consistent product quality and meeting regulatory standards across different manufacturing batches presents ongoing challenges for manufacturers. This situation is particularly difficult for smaller companies entering the market, as they often encounter resource constraints and technical hurdles that limit their capabilities. Furthermore, the increasing emphasis on product quality and regulatory compliance adds to the complexities and costs of manufacturing. To address these challenges, the industry is investing in advanced manufacturing technologies and process optimization, which can enhance efficiency and reduce production costs while maintaining product quality. These initiatives aim to create a more sustainable production environment, enabling both established and new players to thrive in the competitive landscape of the G-CSF biosimilars market while ensuring access to high-quality treatments for patients in need.

Category-wise Acumens

How will the Dominance of Long-acting G-CSF Drive the Growth of the Type Segment?

Long-acting G-CSF's dominance in the Type segment is significantly driving growth in the overall biosimilars market. The improved patient compliance, reduced administration frequency, and enhanced therapeutic outcomes associated with long-acting formulations position them as the preferred choice among healthcare providers and patients. These formulations benefit from established clinical evidence and widespread acceptance in various treatment protocols, reinforcing their market presence.

Continued innovation in drug delivery systems and improved pharmacokinetic profiles further fuels the market leadership of long-acting G-CSF. The development of new formulations and administration devices has successfully expanded the patient base and improved treatment adherence. Additionally, the convenience of administration and fewer hospital visits contribute to its success, particularly in ambulatory care settings. As manufacturing technology advances and patient preferences evolve, the long-acting segment is expected to maintain its growth momentum through ongoing product innovation and strategic market expansion. This focus on enhancing patient experience and treatment outcomes will be pivotal in sustaining the long-acting G-CSF segment's leadership in the biosimilars market.

How will the Growing Importance of Hospital Pharmacies Drive the Expansion of The Distribution Channel Segment?

The dominance of hospital pharmacies in G-CSF biosimilar distribution highlights the critical role of institutional healthcare providers in managing complex biological treatments. Hospital pharmacies are equipped with specialized storage facilities, trained personnel, and integrated care coordination essential for handling biological products. This capability is particularly vital for maintaining product integrity and ensuring proper administration.

Additionally, hospital pharmacies enable direct interaction between healthcare providers and patients, allowing for better monitoring and management of treatment outcomes. Their ability to provide comprehensive patient care while adhering to cold chain requirements makes hospital pharmacies an ideal distribution channel for G-CSF biosimilars. Consequently, we can anticipate increased investment in hospital pharmacy infrastructure and staff training to improve the efficiency of biological product handling. Innovations in inventory management systems and patient care coordination within the hospital pharmacy segment will facilitate more effective distribution and utilization of G-CSF biosimilars. This focus on enhancing hospital pharmacy capabilities is essential for ensuring that patients receive high-quality care and access to necessary treatments

Country/Region-wise Acumens

Will the Advanced Healthcare Infrastructure Drive the Dominance of North America in The G-CSF Biosimilars Market?

The dominance of North America in the G-CSF biosimilars sales market is significantly driven by its advanced healthcare infrastructure and robust regulatory framework. The region's early adoption of biosimilars, bolstered by favorable reimbursement policies and healthcare cost containment initiatives, has established a strong market foundation. This favorable context is enhanced by high awareness among healthcare providers and patients regarding the benefits of biosimilars. North America's leadership in oncology treatment and supportive care has further solidified its position in the G-CSF biosimilars market. The region's substantial investment in healthcare technology and a strong emphasis on evidence-based medicine have facilitated broader acceptance of biosimilar products. Additionally, the presence of major pharmaceutical companies and research institutions fosters continuous innovation and market growth, ensuring North America remains a key market for G-CSF biosimilar manufacturers and developers. As the market evolves, ongoing collaborations and advancements in biosimilar development are expected to reinforce North America's dominant position in the global G-CSF biosimilars landscape.

Will the Growing Healthcare Access Drive the Expansion of The G-CSF Biosimilars Market in Asia-Pacific?

The rapidly improving healthcare access in the Asia-Pacific region is a key driver of expansion in the G-CSF Biosimilars sales Market, presenting significant growth opportunities. With large patient populations and increasing healthcare investments, countries like China, India, and Japan are witnessing substantial growth in biosimilar adoption. This trend is fueled by government initiatives aimed at improving healthcare accessibility, rising healthcare expenditure, and growing insurance coverage. As healthcare systems expand, the demand for cost-effective biological treatments increases, enhancing opportunities for biosimilar manufacturers. The region's evolving regulatory landscape, where authorities are establishing clearer pathways for biosimilar approval, further propels this growth. Innovations in local manufacturing capabilities, coupled with strategic partnerships between global and regional players, are accelerating market development. This collaborative environment is establishing the Asia-Pacific region as a crucial market for G-CSF biosimilar manufacturers. Furthermore, as awareness of biosimilars grows among healthcare providers and patients, the region is poised for continued expansion in the biosimilars sector, reflecting a shift towards sustainable healthcare solutions.

Competitive Landscape

The G-CSF biosimilars sales market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the G-CSF biosimilars sales market include:

Sandoz (Novartis)

Pfizer Inc.

Teva Pharmaceutical Industries

Amgen Inc.

Reddy's Laboratories

Coherus BioSciences

Biocon

Intas Pharmaceuticals

Mylan N.V. (Now Viatris)

Kashiv BioSciences

Latest Development

1 INTRODUCTION OF GLOBAL G-CSF BIOSIMILARS SALES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL G-CSF BIOSIMILARS SALES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL G-CSF BIOSIMILARS SALES MARKET, BY TYPE

5.1 Overview
5.2 Short-acting G-CSF
5.3 Long-acting G-CSF

6 GLOBAL G-CSF BIOSIMILARS SALES MARKET, BY APPLICATION

6.1 Overview
6.2 Blood Disorders
6.3 Oncology Diseases
6.4 Chronic Diseases
6.5 Others (Acute Radiation Syndrome)

7 GLOBAL G-CSF BIOSIMILARS SALES MARKET, DISTRIBUTION CHANNEL

7.1 Overview
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies
7.5 Others (Specialty Clinics)

8 GLOBAL G-CSF BIOSIMILARS SALES MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL G-CSF BIOSIMILARS SALES MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Sandoz (Novartis)
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Teva Pharmaceutical Industries
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Amgen Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Reddy's Laboratories
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Coherus BioSciences
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Biocon
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Intas Pharmaceuticals
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Mylan N.V. (Now Viatris)
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Kashiv BioSciences
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 AbbVie
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments